Dr. Avtar Dhillon, M.D. is the co-founder, of OncoSec Medical Inc (OTCBB: ONCS). Some of you may recognize Dr. Dhillon as the former President & Chief Executive Officer of Inovio Pharmaceuticals (AMEX:INO).
Dhillon served at that company from 2001 through 2009 and he successfully led the turnaround of that firm through a restructuring, acquisition of technology from several European and North American companies, and a merger with VGX Pharmaceuticals. As we reported Wednesday, Inovio announced that its first quarter revenues had significantly increased (+$3.1 million, up from $1.4 million in the year-ago).
Based in San Diego, California, this new company aims to improve the quality and performance of treatments for patients with all types of solid tumor cancers using "Precision Tumor Destruction" by using a combination of hardware and drugs (electro-chemical tumor ablation and electro-immunotherapy with DNA based cytokines).
I ran into Dr. Dhillon at the recent Roth Investment Conference in Southern California and some of the results for his platform were impressive, particularly since the technology has already shown efficacy and strong safety profile in 400+ patients during clinical trials involving cutaneous (BCC, SCC, melanoma), head & neck, breast, prostate, and pancreatic tumors.
OncoSec's innovative research and the advancement of a new “electro-oncology” therapy has obviously started to gain the attention of early investors as well. Yesterday the company announced the appointment of three members to its leadership team and while most of the markets were down, their stock continued to climb- albeit modestly. Not bad for a company whose name is not yet widely known.
Formed earlier this year, OncoSec expects to initiate Phase II clinical trials for its tumor-destroying, tissue-sparing ElectroOncology therapies before the end of this year and we recommend that you watchlist the stock and learn more about their very interesting approach to selective killing of cancer cells while preserving healthy tissue.
Chemical based ablation, unlike surgery, radio frequency ablation and cryotherapy that has the ability to selectively kill cancer. Studies demonstrate the therapy to be a safe, easy to use,
economical and highly effective alternative to surgery and OncoSec’s plan is to maximize the likelihood of clinical and regulatory success.
The platform's Improved cosmetic, functional and pain outcomes would be welcomed by patients who suffer from these types of tumors.
While the company feels the near-term commercial potential is there for this ElectroOncology therapy, they will obviously have to fight for adoption within the oncology community. A minimal upfront investment for the equipment should help and a recurring sales model (single use disposable) component has been built into the revenue model. That should provide an on-going revenue stream to OncoSec.
The technology enters the biotech trading space at Phase II for several cancer indications based on positive Phase I clinical data. Unlike other recently introduced biotech plays, the science has notched some early victories in the pipeline process, so some of the inherently early risk is off the table.
The share structure and early valuation pricing also appears to point towards the possibility of a faster than normal uplisting to a larger exchange. Such a move would be welcome by institutions and funds already familiar with Dr. Dhillon's leadership track record who might want to also invest in his new venture.
Some select slides from their investor presentation can be found below (click to enlarge).
If you're interested in learning more, you can download the complete presentation from the BioMedReports research and reports section here: OncoSec Investor Presentation
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.